Cargando…
Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan
Lafora disease (LD, OMIM #254780) is a rare, recessively inherited neurodegenerative disease with adolescent onset, resulting in progressive myoclonus epilepsy which is fatal usually within ten years of symptom onset. The disease is caused by loss-of-function mutations in either of the two genes EPM...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578133/ https://www.ncbi.nlm.nih.gov/pubmed/28800070 http://dx.doi.org/10.3390/ijms18081743 |
_version_ | 1783260476972466176 |
---|---|
author | Sullivan, Mitchell A. Nitschke, Silvia Steup, Martin Minassian, Berge A. Nitschke, Felix |
author_facet | Sullivan, Mitchell A. Nitschke, Silvia Steup, Martin Minassian, Berge A. Nitschke, Felix |
author_sort | Sullivan, Mitchell A. |
collection | PubMed |
description | Lafora disease (LD, OMIM #254780) is a rare, recessively inherited neurodegenerative disease with adolescent onset, resulting in progressive myoclonus epilepsy which is fatal usually within ten years of symptom onset. The disease is caused by loss-of-function mutations in either of the two genes EPM2A (laforin) or EPM2B (malin). It characteristically involves the accumulation of insoluble glycogen-derived particles, named Lafora bodies (LBs), which are considered neurotoxic and causative of the disease. The pathogenesis of LD is therefore centred on the question of how insoluble LBs emerge from soluble glycogen. Recent data clearly show that an abnormal glycogen chain length distribution, but neither hyperphosphorylation nor impairment of general autophagy, strictly correlates with glycogen accumulation and the presence of LBs. This review summarizes results obtained with patients, mouse models, and cell lines and consolidates apparent paradoxes in the LD literature. Based on the growing body of evidence, it proposes that LD is predominantly caused by an impairment in chain-length regulation affecting only a small proportion of the cellular glycogen. A better grasp of LD pathogenesis will further develop our understanding of glycogen metabolism and structure. It will also facilitate the development of clinical interventions that appropriately target the underlying cause of LD. |
format | Online Article Text |
id | pubmed-5578133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-55781332017-09-05 Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan Sullivan, Mitchell A. Nitschke, Silvia Steup, Martin Minassian, Berge A. Nitschke, Felix Int J Mol Sci Review Lafora disease (LD, OMIM #254780) is a rare, recessively inherited neurodegenerative disease with adolescent onset, resulting in progressive myoclonus epilepsy which is fatal usually within ten years of symptom onset. The disease is caused by loss-of-function mutations in either of the two genes EPM2A (laforin) or EPM2B (malin). It characteristically involves the accumulation of insoluble glycogen-derived particles, named Lafora bodies (LBs), which are considered neurotoxic and causative of the disease. The pathogenesis of LD is therefore centred on the question of how insoluble LBs emerge from soluble glycogen. Recent data clearly show that an abnormal glycogen chain length distribution, but neither hyperphosphorylation nor impairment of general autophagy, strictly correlates with glycogen accumulation and the presence of LBs. This review summarizes results obtained with patients, mouse models, and cell lines and consolidates apparent paradoxes in the LD literature. Based on the growing body of evidence, it proposes that LD is predominantly caused by an impairment in chain-length regulation affecting only a small proportion of the cellular glycogen. A better grasp of LD pathogenesis will further develop our understanding of glycogen metabolism and structure. It will also facilitate the development of clinical interventions that appropriately target the underlying cause of LD. MDPI 2017-08-11 /pmc/articles/PMC5578133/ /pubmed/28800070 http://dx.doi.org/10.3390/ijms18081743 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sullivan, Mitchell A. Nitschke, Silvia Steup, Martin Minassian, Berge A. Nitschke, Felix Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan |
title | Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan |
title_full | Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan |
title_fullStr | Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan |
title_full_unstemmed | Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan |
title_short | Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan |
title_sort | pathogenesis of lafora disease: transition of soluble glycogen to insoluble polyglucosan |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578133/ https://www.ncbi.nlm.nih.gov/pubmed/28800070 http://dx.doi.org/10.3390/ijms18081743 |
work_keys_str_mv | AT sullivanmitchella pathogenesisoflaforadiseasetransitionofsolubleglycogentoinsolublepolyglucosan AT nitschkesilvia pathogenesisoflaforadiseasetransitionofsolubleglycogentoinsolublepolyglucosan AT steupmartin pathogenesisoflaforadiseasetransitionofsolubleglycogentoinsolublepolyglucosan AT minassianbergea pathogenesisoflaforadiseasetransitionofsolubleglycogentoinsolublepolyglucosan AT nitschkefelix pathogenesisoflaforadiseasetransitionofsolubleglycogentoinsolublepolyglucosan |